6月4日，据CDE官网消息，苏州星曜坤泽生物制药有限公司联合申请药品“HT-102注射液”，获得临床试验默示许可，受理号CXSB2500026。
公示信息显示，药品“HT-102注射液”适应症：慢性乙型病毒性感染。
苏州星曜坤泽生物制药有限公司，成立于2021年，位于苏州市，是一家以从事医药制造业为主的企业。企业注册资本2053.131万人民币。
通过天眼查大数据分析，苏州星曜坤泽生物制药有限公司共对外投资了1家企业，知识产权方面有商标信息3条，专利信息1条，此外企业还拥有行政许可5个。
主要股东信息显示，苏州星曜坤泽生物制药有限公司由苏州复健星熠创业投资合伙企业（有限合伙）持股47.623%、天津复星海河医疗健康产业基金合伙企业（有限合伙）持股23.8115%、安吉科泉股权投资合伙企业（有限合伙）持股16.8421%、苏州福曜星坤生物技术合伙企业（有限合伙）持股8.1178%、苏州太浩园丰创业投资合伙企业（有限合伙）持股1.0526%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.